Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Metabolon Launches Fourth Generation DiscoveryHD4™ Metabolomics Platform

Published: Saturday, April 05, 2014
Last Updated: Saturday, April 05, 2014
Bookmark and Share
New technology advancements have potential to lead the way to new scientific breakthroughs, novel biomarkers and discoveries, and support diagnostic product pipeline.

Metabolon, Inc. has announced the launch of DiscoveryHD4™, the company’s fourth-generation metabolomics platform.

This new technology platform will empower the company's metabolomics TrueVision™, mVision™ and mView™ research and biomarker discovery offerings, as well as its diagnostic product development pipeline.

Further extending Metabolon's leadership position in metabolomics research and diagnostics, this platform enables a more expansive and precise global biochemical coverage of metabolite markers across the entire metabolome, thus increasing the ability to discover novel biomarkers and research questions.

Two key innovations power the DiscoveryHD4™ platform advancements. First, accurate mass instrumentation coupled to our new software technology provides a profound increase in sensitivity, and leads to the detection of more metabolites with greater precision.

Second adding a hydrophilic interaction chromatography (HILIC) method to the company’s standard platform technology provides a more complete picture for metabolites within central carbon, or “energy,” metabolism, among other advances.

The novel software tools that Metabolon has pioneered leverages these technical advancements. Together with Metabolon’s wealth of biochemistry expertise, these advancements are significant ingredients to Metabolon’s leadership and success in metabolomics.

“This new technology platform advances the evolution of our metabolomics capabilities and intellectual property,” said John Ryals, Ph.D, President and CEO of Metabolon. “These capabilities are a primary reason we are seeing more collaborations with large initiatives such as the one we recently announced with Craig Venter’s new genomics initiative, Human Longevity Inc. There is growing recognition of the value metabolomics offers to empower genomics and connect genetics to the phenotype, or the living system’s observable characteristics. Having a metabolomics technology platform with an industrialized capability and a capacity that can keep pace with the power of modern sequencing technologies is important to maintaining our position of industry leadership. The breadth of metabolome coverage that this new platform now provides enables more mechanistic insight into the basis of human health and disease.”

“Our scientists are ecstatic about the enhanced resolving power that the DiscoveryHD4™ will deliver our clients across academia and the biotechnology industry. We are already leveraging the enhanced resolving power of the new platform to fuel our diagnostic biomarker discovery pipeline,” commented Michael Milburn, Ph.D., Chief Scientific Officer of Metabolon.

Milburn continued, “Not only are we able to identify more metabolite markers than ever before, we have extended our capabilities to routinely measure additional classes such as steroids and energy metabolites. With these advancements, we can take a complex sample, such as blood, and rapidly identify and rigorously quality control up to 1,000 metabolites in a single biological sample, more than many have thought possible. Practically, this means our potential to discover more sensitive and specific biomarkers and understand what these signatures mean for the underlying biology is dramatically heightened.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Global Genomics Group and Metabolon to Collaborate
Metabolon will conduct biochemical profiling in single largest prospective pan-omic study.
Thursday, November 14, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
Biomarker for Parkinson's Disease Found in Urine Samples
Protein identified as Parkinson's biomarker sourced from patient's stored frozen urine samples.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!